Decreased plasma concentrations of high-density lipoproteins (HDL) make part of the
lipoprotein abnormalities encountered in end-stage liver disease [
[1]
,
[2]
]. The liver plays a central role in both the production and metabolism of various
lipoprotein classes, and produces enzymes such as lecithin:cholesterol acyltransferase
(LCAT) and hepatic lipase which are critically involved in HDL metabolism [
[1]
,
[2]
]. LCAT is required for the esterification of free cholesterol to cholesteryl esters,
thereby enabling HDL maturation, whereas hepatic lipase hydrolyses triglycerides in
various lipoproteins including HDL [
[2]
,
[3]
]. Yet, decreased plasma levels of HDL cholesterol or of its major apolipoprotein,
apoAI, do not make part of prognostic tools for liver disease severity categorization
such as the Child Pugh Turcotte (CPT) classification or the model for end-stage liver
disease (MELD) score.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Plasma lipids and lipoproteins in liver disease.Gut. 1978; 19: 526https://doi.org/10.1136/gut.19.6.526
- Abnormalities of lipoprotein levels in liver cirrhosis: clinical relevance.Digest Dis Sci. 2018; 63: 16-26https://doi.org/10.1007/s10620-017-4862-x
- Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020.Curr Opin Lipidol. 2020; 31: 232-237https://doi.org/10.1097/mol.0000000000000697
- HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.J Hepatol. 2020; 73: 113-120https://doi.org/10.1016/j.jhep.2020.01.026
- Profoundly disturbed lipoproteins in cirrhotic patients: role of lipoprotein-Z, a hepatotoxic LDL-like lipoprotein.J Clin Med. 2022; 11: 1223https://doi.org/10.3390/jcm11051223
- Characterization of LP-Z lipoprotein particles and quantification in subjects with liver disease using a newly developed NMR-based assay.J Clin Med. 2020; 9: 2915https://doi.org/10.3390/jcm9092915
- Lipoprotein Z, a novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.Hepatology. 2021; (Online ahead of print)https://doi.org/10.1002/hep.32203
Article info
Publication history
Published online: April 01, 2022
Accepted:
March 29,
2022
Received in revised form:
March 27,
2022
Received:
March 16,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
